306% growth capturing channel, category, and innovation in clean-ingredient food, next generation skincare, and plant-based wellness

VANCOUVER, BC , May 4, 2023 /CNW/ – Simply Better Brands Corp. (“SBBC” or the “Company”) (TSXV: SBBC) (OTCQB: PKANF) is pleased to announce its unaudited financial results for the year ended December 31, 2022. All amounts are expressed in United States dollars unless otherwise noted. Certain metrics, including those expressed on an adjusted basis, are non-International Financial Reporting Standards (“IFRS”) measures, see “Non-IFRS Measures” below.  The Company expected to file its audited financial statements for the year ended December 31, 2022 and management discussion and analysis shortly.

2022 YEAR KEY COMMERCIAL ACHIEVEMENTS

• TRUBAR Protein Bar: In additional to supporting a U.S. and Canadian-based retailers base, TRUBAR was able to expand into roughly 50% of U.S. and Canadian Costco Clubs throughout 2022. As TRUBAR exceeded the bar category sales velocities at Costco, TRUBAR is currently in national distribution at Costco. Supporting the brands continued expansion are four initiatives: manufacturing capacity expansion, continued omni-channel distribution growth, bar flavor extensions, and the entry into the $8 billion protein powder category in 2023.

• PureKana Wellness: PureKana, a leading plant-based wellness brand, remained focused on a its customer acquisition initiative, adding over 18,700 customers per month and enabling the sales funnel into a subscription model. To expand beyond human consumption, PureKana announced its 2023 entry into the $196 million hemp-based pet category with offerings in with calming chews, hip & joint chews, and hair & coat drops. As an estimated 60% of PureKana’s loyal customers have pets, the growth opportunity is sizeable.

• No B.S. Skincare: Originally, the No B.S. brand was sourced exclusively online at livenobs.com and Amazon. In 2022, the brand entered 3,200 CVS Health stores for a Back-to-School Event and continues to maintain a on shelf presence in CVS’s healthy skin section. Initial brick and mortar success has the brand slotted to enter an additional large, national chain in summer 2023. Sources of growth include omni-channel expansion supported by insight-driven innovation with an expanded facial acne patch portfolio (overnight pimple patch and acne patch plus retinol night cream) and a natural deodorant category entry.

• Vibez Wellness: The Vibez Wellness line was launched in November 2022 to capture incremental millennial consumers on their preventative wellness journey. With an initial keto gummy supplement offering, the brand achieved $1.4M in revenue in the first 60 days of launch. Vibez’s primary focus is non-CBD solutions into the weight management, focal acuity, and healthy hair consumer need states.

“As our strong 2022 financial and commercial results illustrate, we are positioned for continued revenue growth, profit improvement, and debt reduction in 2023. Our strategic priorities remain to lead consumer-centric innovation and relentlessly acquire customers to these emerging brands by driving category and channel expansion. With our recent $7 million finance raise, we are aptly fueled to deliver the 2023 outlook of $80 million in revenue and $3-4 million in adjusted EBITDA at a gross margin target range of 58-60%,” says SBBC CEO, Kathy Casey.

UNAUDITED FINANCIAL HIGHLIGHTS FOR YEAR ENDED DECEMBER 31, 2021

For the twelve months ended December 31, 2022, the Company generated revenue of $65.4 million with a gross profit of $44.6 million (68%) compared to $15.6 million with a gross profit of $9.7 million (62%) during the twelve months ended December 31, 2021.  Revenue increased by $49.8 million (319% increase) over the prior year’s revenues.

Operating costs for the twelve months ended December 31, 2022, were $54.3 million, an increase of $34.8 million (178%), compared to $19.5 million for the twelve months ended December 31, 2021.

During the twelve months ended December 31, 2022, the Company recorded a net loss of $11.1 million compared to a net loss of $12.8 million for the twelve months ended December 31, 2021.

For the three months ended December 31, 2022, the Company generated revenue of $23.0 million with a gross profit of $16.1 million (70%) compared to $6.5 million with a gross profit of $4.3 million (66%) during the three months ended December 31, 2021.  Revenue increased by $16.5 million (254% increase) over the prior period’s revenues.

Operating costs for the three months ended December 31, 2022, were $19.9 million, an increase of $13.0 million (188%), compared to $6.9 million for the three months ended December 31, 2021.

During the three months ended December 31, 2022, the Company recorded a net loss of $4.2 million compared to a net loss of $4.2 million for the three months ended December 31, 2021.

Non-IFRS Measures (Earnings before Interest, Taxes, Depreciation, and Amortization (“EBITDA”) and Adjusted EBITDA)

EBITDA and Adjusted EBITDA are non-IFRS measures used by management that are not defined by IFRS. EBITDA and Adjusted EBITDA do not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures presented by other issuers. Management believes that EBITDA and Adjusted EBITDA provide meaningful and useful financial information as these measures demonstrate the operating performance of the business excluding non-cash charges.

The most directly comparable measure to EBITDA and Adjusted EBITDA calculated in accordance with IFRS is net loss. The following table presents the EBITDA and Adjusted EBITDA for the twelve months ended December 31, 2022, and 2021, and a reconciliation of same to net income (loss):

The Company has an adjusted EBITDA of $1.2 million for the year ended December 31, 2022, an increase of $4.5 million over the adjusted EBITDA loss for the comparable period in 2021.

The Company generated positive adjusted EBITDA of $0.6 million for the three months ended December 31, 2022, an increase of $1.7 million over the adjusted EBITDA loss for the comparable period in 2021.

Readers are cautioned that EBITDA and Adjusted EBITDA should not be construed as an alternative to net income as determined under IFRS; nor as an indicator of financial performance as determined by IFRS; nor a calculation of cash flow from operating activities as determined under IFRS; nor as a measure of liquidity and cash flow under IFRS. The Company’s method of calculating EBITDA and Adjusted EBITDA may differ from methods used by other companies and, accordingly, the Company’s EBITDA and Adjusted EBITDA may not be comparable to similar measures used by any other company. Except as otherwise indicated, EBITDA and Adjusted EBITDA are calculated and disclosed by SBBC on a consistent basis from period to period.  Specific adjusting items may only be relevant in certain periods.

See also Earnings before Interest, Taxes, Depreciation, and Amortization (“EBITDA”) and Adjusted EBITDA (Non-GAAP Measures) in the Company’s management discussion and analysis for the year ended December 31, 2022 available on SEDAR at www.sedar.com.

Liquidity and Capital Resources

The Company’s primary liquidity and capital requirements are for inventory and general corporate working capital purposes. The Company had a cash balance of $2.3 million as of December 31, 2022, which will provide capital to support the planned growth of the business and for general corporate working capital purposes. The Company’s working capital deficiency decreased from $11.8 million as of December 31, 2021, to a working capital deficiency of $9.3 million as of December 31, 2022 ($2.5 million decrease). Working capital deficiency included the Mainstreet loan ($10.3 million) which is classified as current whereas the term is for 5 years maturing in December 2025.  The Mainstreet loan has a five-year term with principal repayments due to start in December 2023 with the first $1.5 million principal repayment. This loan has several covenants including annual and quarterly reporting and debt service coverage. The Company was not compliant with the debt service covenant as of December 31, 2022 although it made progress in improving the Adjusted EBITDA performance of Purekana LLC during the year. For example, adjusted EBITDA reported for Purekana LLC for the year ended December 31, 2022 was $1.4 million compared to an adjusted EBITDA loss of $1.4 million for the year ended December 31, 2021 or a $2.8 million improvement. No notice of default has been received by the Company as of the date of this news release and the Company has been paying the interest on a regular basis. It has been classified as current as a result of the noncompliance with the debt service covenant.

The Company continues to focus on improving its working capital position through a number of initiatives including equity and convertible debt private placements, issuance of promissory notes and establishment of lines of credit for its subsidiaries.

Private Placements

The Company completed a private placement raise in August of 2022 and raised CA$3,990,844 ($3,069,880) in common shares and convertible debentures. The funds raised were used for debt reduction and working capital.

Subsequent to the year ended December 31, 2022, The Company raised an additional CA$7,000,000 in equity to be used for further debt reduction, working capital and for growth initiatives in 2023.

Convertible Debentures

During the year ended December 31, 2022, the Company reduced the balance of convertible debentures outstanding by $1.0 million.  Subsequent to the year ended December 31, 2022, The Company paid down $1.7 million in convertible debentures including accrued interest that were due in February 2023.

Line of Credit Facilities

The Company has secured several lines of credit facilities for three of its subsidiaries to support the financing of purchase orders from key customers. These lines of credit have been critical to finance the large retail purchase orders the Company’s subsidiaries have successfully generated during the year ended December 31, 2022.  For more information of the line of credit facilities please refer to note 10 in the financial statements for the year ended December 31, 2022.  During the year ended December 31, 2022, the Company raised over $8 million in funds from these lines of credit to finance purchase orders from its large retail customers. Over the same period, the Company repaid over $5.9 million of these credit facilities to the lender. TRU was able to increase its primary line of credit with this lender to $6 million in December 2022. The nature of these loans is to turnover between 3-5 months from the time the money is advanced to repayment.

Promissory Notes

During the year ended December 31, 2022, the Company reduced the balance of promissory notes outstanding by approximately $3.5 million.  All promissory notes paid off during the year had a maturity less than 12 months.

The Company was able to secure a $1 million promissory note with a duration of 42 months during the year for debt reduction and working capital. The loan bears 15% interest per annum and will be repaid over 42-months starting November 15, 2022.

The Company entered into an agreement with the third party to settle the payment of the assigned portion of the PK Promissory Notes ($1,166,168). The Company made payments totaling $350,000 to the assigned portion of the PK Promissory Notes during the year. The agreement calls for monthly payments of $50,000 which began on December 15, 2022, and continues until the $1,166,168 amount is paid in full. The note bears an interest rate of 6%.

2023 OUTLOOK

For our 2023 Outlook:

1. The Company’s expectation for consolidated net sales to exceed $80 million.
2. The Company expects gross margin as a percentage of net sales to be between 58% and 60%.
3. The Company expects to achieve positive Adjusted EBITDA in the range of $3-4 million.

The Company is also reported on preliminary sales for the first quarter of fiscal 2023 of $24.8 million compared to $12.1 million in Q1 2022 or a 205% increase. Preliminary gross profit for the first quarter of 2023 is 55% compared to 66% in the first quarter of 2022. The lower gross margin is due to sales channel mix as a larger portion of sales to retailers compared to the prior year’s predominantly online sales delivery.

About Simply Better Brands Corp.

Simply Better Brands Corp. leads an international omni-channel platform with diversified assets in the emerging plant-based and holistic wellness consumer product categories. The Company’s mission is focused on leading innovation for the informed Millennial and Generation Z generations in the rapidly growing plant-based, natural, and clean ingredient space. The Company continues to focus on expansion into high-growth consumer product categories including plant-based food, clean ingredient skincare and plant-based wellness. For more information on Simply Better Brands Corp., please visit: https://www.simplybetterbrands.com/investor-relations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

Certain statements contained in this news release constitute “forward-looking information” and “forward looking statements” as such terms are used in applicable Canadian securities laws. Forward-looking statements and information are based on plans, expectations and estimates of management at the date the information is provided and are subject to certain factors and assumptions, including, among others, that the Company’s financial condition and development plans do not change as a result of unforeseen events, the impact of the COVID-19 pandemic, the regulatory climate in which the Company operates, and the Company’s ability to execute on its business plans. Specifically, this news release contains forward-looking statements relating to, but not limited to: entry into the $8 billion protein powder category in 2023, expansion plans for TRU Brands products, filing of the Company’s audited financial statements for the year ended December 31, 2022 and management discussion and analysis and, success of the Company’s marketing efforts.

Forward-looking statements and information are subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking statements and information. Factors that could cause the forward-looking statements and information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company’s financial condition and development plans change, ability to obtain necessary regulatory approvals for proposed transactions, as well as the other risks and uncertainties applicable to the plant-based food, clean ingredient skincare and plant-based wellness or broader wellness industries and to the Company, and as set forth in the Company’s annual information form available under the Company’s profile at www.sedar.com.

The above summary of assumptions and risks related to forward-looking statements in this news release has been provided in order to provide shareholders and potential investors with a more complete perspective on the Company’s current and future operations and such information may not be appropriate for other purposes. There is no representation by the Company that actual results achieved will be the same in whole or in part as those referenced in the forward-looking statements and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities law.

Financial Outlook

This press release contains future-oriented financial information and financial outlook information (collectively, “FOFI“) about the financial results the quarter ended March 31, 2023, and the year ended December 31, 2022, including net sales, gross margin, and Adjusted EBITDA, all of which are subject to the same assumptions, risk factors, limitations, and qualifications as set out under the heading “Forward-Looking Information”. The actual financial results of the Company may vary from the amounts set out herein and such variation may be material. The Company and its management believe that the financial outlook has been prepared on a reasonable basis, reflecting management’s best estimates and judgments and the FOFI contained in this press release was approved by management as of the date hereof. However, because this information is subjective and subject to numerous risks, it should not be relied on as necessarily indicative of future results. Except as required by applicable securities laws, the Company undertakes no obligation to update such FOFI. FOFI contained in this press release was made as of the date hereof and was provided for the purpose of providing further information about the Company’s anticipated future business operations on a quarterly and annual basis. Readers are cautioned that the FOFI contained in this press release should not be used for purposes other than for which it is disclosed herein.

SOURCE Simply Better Brands Corp

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Egyptian Market Growing 15% Annually

CAVE CREEK, AZ, March 15, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Endexx Corporation (OTC:EDXC), a provider of innovative, plant-based, and sustainable health and skincare products, announced today that its HYLA team secured a distribution agreement and purchase order contract to sell in Egypt.  The contract exceeds $1,000,000 USD for the next 12 months, with an opening order at $200,000 USD.

According to market statistics sourced on Statista, 24% of the population in Egypt smoke a variety of tobacco products. Vape products are growing at an annual rate of 15% with over $370 million in e-cigarettes revenues in 2022. Hyla products are anticipated to be a well-received product in this market offering an alternative to nicotine-based products.

CEO of Endexx Todd Davis stated, “HYLA continues to rapidly expand in multiple international markets as demand for non-nicotine vape alternatives by Hyla continue to fill a major demand void and vacuum in the market.” Davis added, “Better Products, Better You”, Endexx continues to provide the best products that fit our motto for the past 10 years, and HYLA products are proving to exceed expectations.”

Visit: www.TryHyla.com

0% Nicotine. 100% Plant Powered

About Endexx Corporation

Endexx Corporation develops and distributes all natural, plant-derived topical skincare products.  Its products vary from balms, creams, lotions, butters, masks, scrubs, and oils, all with the shared purpose of healthy skin and grooming wellness.  The science behind these products involves a decade of clinical research in the field and lab work to provide functional formulation with ingredients for optimal absorption and support of skin health. www.endexx.com

“Better Products, Better You”©

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

We caution that any forward-looking statements (as such term is defined in the U.S. Private Securities Litigation Reform Act of 1995) contained in this press release or made by us, our management, or our spokespeople involve risks and uncertainties and are subject to change based on various factors, many of which are beyond our control. Accordingly, our future performance and financial results may differ materially from those expressed or implied in any such forward-looking statements. Forward-looking statements include, without limitation, statements regarding our future operating results, the implementation and impact of our strategic plans, and our ability to meet environmental, social, and governance goals. Words such as “estimate,” “commit,” “target,” “goal,” “project,” “plan,” “believe,” “seek,” “strive,” “expect,” “anticipate,” “intend,” “potential” and any similar expressions may identify forward-looking statements. Risks associated with the following factors, among others, could affect our financial performance and cause actual results to differ materially from those expressed or implied in any forward-looking statements:

Except as may be required by law, we assume no obligation and do not intend to make publicly available any update or other revisions to any of the forward-looking statements contained in this press release to reflect circumstances existing after the date of this press release or to reflect the occurrence of future events, even if experience or future events make it clear that any expected results expressed or implied by those forward-looking statements will not be realized. More information on potential factors that could affect our results is included “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2022.

For further information, please contact:
Endexx Corporation
Endexx@endexx.com
480-595-6900

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The Mixed Martial Artist, dubbed the Venezuelan Vixen, will collaborate to drive brand awareness as No BS expands omni-channel

Julianna Pena

VANCOUVER, British Columbia, March 10, 2022 (GLOBE NEWSWIRE) — Simply Better Brands Corp. (the “Company” or Simply Better Brands”) (TSX Venture: SBBC) (OTCQB: PKANF) is pleased to announce a sponsorship agreement and collaboration between Simply Better Brand’s subsidiary, No B.S. Life, LLC (“No B.S. Skincare” or “No B.S.”) and Julianna Peña, the mixed martial artist who won the UFC Women’s Bantamweight Championship this past December and was named MMA Junkie’s Female Fighter of the Year.

“Julianna represents what No B.S. Skincare is about, she is an amazing inspiration, breaking stereotypes from all angles. Being a woman does not mean we can’t be strong and win UFC championships and being a fighter does not mean we can’t take care of how our face looks. If you want your skin to look good, it must be healthy. This is why we developed a skincare line with no toxic ingredient or BS and this is why Julianna is the perfect partner to inspire people to break stereotypes and cut out all of the unnecessary, toxic BS they don’t need, starting with their skin care,” says Diana Briceno, CEO and founder of No B.S. Skincare.

The sponsorship encompasses curated and authentic content consistent with No B.S. brand’s authentic positioning ultimately, driving brand awareness via social media integration, public relation activation, and potential product innovation collaboration.

“As a professional athlete and champion, the most important standard I set for myself is to be the best. I have no tolerance for BS which is why I am so excited to be joining the No B.S. Skincare team. I don’t skip steps in training and I don’t skip steps in my skincare routine. I only put clean products on my skin. And No B.S. Skincare provides the one of the cleanest products on the market. It’s an honor to be able to share my love for No B.S. with the public and help them benefit from these amazing products,” says Julianna Peña.

Originally built as a direct-to-consumer brand, No B.S. will leverage Julianna to continue its omni-channel expansion in 2022. Now with a presence at Amazon and Target, the brand is gaining traction in the drug class of trade with a commitment to enter CVS this year. “The trusted and transparent brand of No B.S. resonates with today’s consumers as part of their wellness transformation. We consistently acquire loyal users lapsing from large mass brands with less clean formulas. Our focus is now on continued science-led innovation and ubiquitous distribution to meet increased demand,” said Kathy Casey, Simply Better Brands’ CEO.

Shares for Services

No B.S. entered into a brand ambassador agreement (the “Agreement”) ‎with Julianna Peña dated March 1, 2022. Julianna Peña is arm’s-length ‎to No B.S. and the Company. Pursuant to the Agreement, Julianna Peña has agreed to act as a brand ambassador for No B.S., providing certain online posts, endorsements and social media content. In consideration for the services provided under the Agreement, No B.S. has agreed to pay Julianna Peña an engagement fee of USD$100,000 (the “Engagement Fee”), a royalty fee equal to 10% of the gross revenues generated from sales achieved by No B.S. from certain sales, and a one-time bonus of USD$25,000 in the event the campaign generates a minimum of USD$500,000 in gross revenues. Each of these amounts payable is payable in common shares of the Company (“Common Shares”) or cash, at the discretion of No B.S. and subject to approval of the TSX Venture Exchange. The Engagement Fee is payable in four ‎equal installments, to be paid quarterly commencing on May 1, 2022. The other fees will be payable upon achievement of the associated sales targets. The number of ‎Common Shares shall be determined based on the 10-day volume weighted average price of ‎the Common Shares on the payment date, and shall not be lower than the Discounted Market ‎Price (as defined by the TSX Venture Exchange). The term of the Agreement is one (1) ‎year.‎

About Simply Better Brands Corp.

Simply Better Brands Corp. leads an international omni-channel platform with diversified assets in the emerging plant-based and holistic wellness consumer product categories. The Company’s mission is focused on leading innovation for the informed Millennial and Generation Z generations in the rapidly growing plant-based, natural, and clean ingredient space. The Company continues to focus on expansion into high-growth consumer product categories including CBD products, plant-based food and beverage, and the global pet care and skin care industries. For more information on Simply Better Brands Corp., please visit: https://www.simplybetterbrands.com/investor-relations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Simply Better Brands Corp.
Brian Meadows
Chief Financial Officer
+1 (855) 553-7441
[email protected]

About No B.S. Skincare
The No B.S. brand is committed to ousting beauty industry B.S. with clean ingredients that work smarter to give us healthy, glowing skin. They don’t promise a miracle in a bottle: they promise clean formulas, visible results, and a B.S.-free beauty culture we can all get behind. They proudly partner with organizations striving to affect real, positive change such as She Recovers, Feeding America, Project Glimmer, and Lotus House.

Forward-Looking Information
Certain statements contained in this news release constitute “forward-looking information” ‎and “forward looking statements” as such terms are used in applicable Canadian securities ‎laws. Forward-looking statements and information are based on plans, expectations and ‎estimates of management at the date the information is provided and are subject to certain ‎factors and assumptions, including, among others, that the Company’s financial condition and ‎development plans do not change as a result of unforeseen events, the impact of the COVID-19 ‎pandemic, the regulatory climate in which the Company operates, and the Company’s ability ‎to execute on its business plans. Specifically, this news release contains forward-looking ‎statements relating to, but not limited to: growth and expansion plans for No B.S. Skincare; impact of No B.S.’ partnership with Julianna Peña; future payments under the Agreement in cash or Common Shares and TSX Venture ‎Exchange approvals of such payments, as required. ‎

Forward-looking statements and information are subject to a variety of risks and uncertainties ‎and other factors that could cause plans, estimates and actual results to vary materially from ‎those projected in such forward-looking statements and information. Factors that could cause ‎the forward-looking statements and information in this news release to change or to be ‎inaccurate include, but are not limited to, the risk that any of the assumptions referred to ‎prove not to be valid or reliable, that occurrences such as those referred to above are realized ‎and result in delays, or cessation in planned work, that the Company’s financial condition and ‎development plans change, as well as the other risks and uncertainties applicable to the CBD ‎or broader wellness industries and to the Company, and as set forth in the Company’s annual ‎information form available under the Company’s profile at www.sedar.com.‎

The above summary of assumptions and risks related to forward-looking statements in this ‎news release has been provided in order to provide shareholders and potential investors with ‎a more complete perspective on the Company’s current and future operations and such ‎information may not be appropriate for other purposes. There is no representation by the ‎Company that actual results achieved will be the same in whole or in part as those referenced ‎in the forward-looking statements and the Company does not undertake any obligation to ‎update publicly or to revise any of the included forward-looking statements, whether as a ‎result of new information, future events or otherwise, except as may be required by applicable ‎securities law. ‎

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

• Marks Real Brands’ first expansion into EU market
• Karanten will be one of the first to carry Real Brands’ new PHAZE Sports line

North Providence, RI, March 09, 2022 (GLOBE NEWSWIRE) — Real Brands Inc. (OTCQB: RLBD) has entered into a strategic distribution partnership with Karanten Ltd. of Budapest, Hungary. Karanten’s initial product launch will feature Real Brands’ WA line of CBD-infused cosmetics and topicals; available at www.warazslat.hu

“Real Brands is pleased to partner with Karanten under their EU license to offer EU customers the calming and healing properties of our Japanese-influenced WA cosmetics developed from decades of research, as well as our wide array of natural products and brands that contribute to health and wellness,” stated Thom Kidrin, Real Brands President and CEO. “This strategic partnership with Karanten marks the first expansion of our brands into the EU market, and we anticipate it will enhance profit margins. Real Brands has been developing new product lines and brands, as well as establishing distribution relationships designed to drive increased shareholder value and provide the public with an opportunity to participate in the growing global hemp-derived CBD market as customers and shareholders.”

Tamas Doffek, Co-Founder of Karanten, added, ”We are excited to enter into this strategic partnership for distribution of Real Brands’ CBD-infused products into the EU. Real Brands has been at the forefront of hemp extraction and CBD-infused products since 2017. As an early entrant into this market, Real Brands has invaluable insight and expertise in formulations and brand development that can leapfrog us forward in delivering tried and true products, as the EU has just recently approved the introduction of Hemp and CBD products. Shortly after our rollout of Real Brands’ WA line of cosmetics and topicals, we plan to expand with Real Brand’s new PHAZE line of sports wellness products in the second quarter of 2022. We look forward to a profitable alliance.”

# # #

Contacts:
Media Relations: Accentuate PR, Julie Shepherd 847 275 3643, [email protected]
Sales/Investors: 617-725-8900, [email protected]

About Real Brands Inc.

Real Brands is the result of a 2020 merger with Canadian American Standard Hemp Inc. (CASH) that brought together industrial scale hemp CBD oil/isolate extraction and processing, wholesaling of CBD oils and isolate, and production and sales of numerous hemp-derived CBD consumer brands of smokable, edible and topical products. Its Halo 5 is a proprietary chromatography extraction technology utilizing a Simulated Moving Bed (SMB) that provides the advantage of producing large quantities of highly purified material and precise pharmaceutical grade molecular separation at dramatically reduced costs. Visit https://www.realbrands.com/. Consumer product lines are available on https://wabrands.com/, https://phazesports.com/, and https://americanstandardhemp.com/.

We invite you to follow us on social media”
https://www.linkedin.com/company/real-brands-inc/
https://twitter.com/RealBrandsInc

About Karaten Ltd.
Karanten is a distributor of hemp-derived cosmetics and well ness products.
For more information, contact: Karantén Ltd. Headquarters via
phone: +36308449747
Website: www.warazslat.hu or
E-mail: [email protected]

Forward-Looking Statements

This release contains certain forward-looking statements and information relating to Real Brands, Inc. (the “Company”) that are based on the current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, the Company. Such statements reflect the current views of the Company with respect to future events and are subject to certain assumptions, including those described in this release. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as “should,” “could,” “will,” “anticipate,” “believe,” “intend,” “plan,” “might,” “potentially” “targeting” or “expect.” Additional factors that could also cause actual results to differ materially relate to the global COVID-19 crisis and other risk factors described in our public filings. The Company does not intend to update these forward-looking statements. The content of the websites referenced above are not incorporated herein.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The THC-Free, CBD derma-cosmetic brand is the first known CBD skincare line to be clinically tested and commercialized across four international markets

The initial launch of Pura H&W will include seven SKUs of proprietary products that will be available through e-commerce as well as cannabis and non-cannabis specific retailers

TORONTO, Dec. 22, 2021 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based pharmaceuticals, is pleased to announce the brand launch and commercialization of its proprietary and clinically backed derma-cosmetics brand, Pura H&W, through its exclusive partnership with Red White and Bloom (CSE: RWB).

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a99e4506-ae98-440d-8190-2ffed5f9fe35

This marks the fourth country in which Avicanna’s derma-cosmetic products branded as Pura H&W or Pura Earth have commercialized, including Colombia and Ecuador as well as Canada where the products are available through medical and adult use channels.

“This marks the first major market for the brand where the products will be accessible to consumers over the counter and nationwide. We are optimistic about the launch of Pura in the United States where we believe the clinically-backed and functional products will be highly differentiated and well supported by our strategic partners Red White and Bloom and their US commercial infrastructure,” commented Aras Azadian, CEO, Avicanna.

The US beauty industry continues to grow rapidly and innovative trends, such as the introduction of cannabinoid-based cosmetics, are expected to provide a strong market opportunity. The launch of the proprietary and clinically-backed cannabidiol (“CBD”) product line will leverage the growing use of online platforms for shopping including Pura H&W’s own e-commerce platform https://www.purahw.com/ in addition to third party e-commerce channels, “big box” retailers and Red White and Bloom’s existing cannabis retail infrastructure across the United States.

“We are excited to launch the Pura brand in the US. As the first clinically tested line in CBD cosmetics, the reaction from our stores and retail partners has been exciting and this is strategically aligned with our goal to be the most recognized and responsible multi state operator (MSO) in the market. We look forward to scaling the launch quickly in both our physical and digital channels,” said Brad Rogers, CEO of Red White & Bloom.

Pura H&W U.S. Portfolio

The skincare line includes seven topical SKUs, three of which are available for purchase online now and for more that are expected to be available imminently.

Anti-Aging Serum: This emulsion gel combines CBD with stem cells from a rare variety of Swiss apple to deliver powerful ingredients to the skin. This refreshing and fast absorbing formula maximizes results for bouncy, glowing skin.

Cooling Body Gel: This go-to essential combines CBD & cannabigerol (“CBG”) with menthol, clove oil and other unique ingredients and natural polyphenols in an advanced emulsion formulation. This non-greasy formula is ideal for those moments when you need to cool and calm areas after physical activity.

Brightening Facial Oil: Made with a blend of natural oils including CBD, Marula, Squalene, Pomegranate and Rosehip, this silky-smooth formula leaves skin looking dewy and revitalized. Light notes of vanilla and limonene refresh the senses.

Anti-Aging Cream: Keeping the skin moisturized and locking in hydration, helps against environmental and natural stressors, and visibly enhances texture. This luxurious combination of CBD and Japanese cedar bud extract floods the skin with moisture to visibly improve natural lifting, toning and smoothing effects.

Intensive Moisturizing Cream: With the hustle and bustle of everyday life, the skin is constantly under assault by stress, pollution, and the environment. These factors can trigger extreme effects which may include the appearance of redness and flaking. This rich combination of CBD and colloidal oatmeal helps soothe extremely dry skin.

Clear Skin Gel: Skin problems due to routine breakouts affect almost all age groups and can occur when hair follicles become blocked by excess oil or dead skin cells. This formulation combining CBD with rosemary extract, tea tree oil and other key ingredients helps to remove oil and provide fresher looking skin.

Skin Protecting Face Lotion (Night): Our overnight cream combines CBD, pro-retinol, and vitamin E, which work together to hydrate the skin while you rest. This smooth formulation helps to boost your skin’s radiance and reduces visible signs of aging.

Clinical Studies

Three cosmetic clinical studies were completed on Avicanna’s [above noted] formulations targeting cosmetic factors associated with aging, acne-prone skin, and eczema-prone skin. The successfully completed studies involved 156 patients that were tested for safety and specific derma-cosmetic endpoints, including hydration and excess oil production. All three studies achieved positive results in the endpoints with no adverse effects, making Pura H&W one of the only cannabinoid consumer lines with human safety and efficacy data. For more information please see www.Clinicaltrials.gov Registry.

About Pura H&W

Pura Health & Wellness (Pura H&W) is Avicanna’s derma-cosmetic line which utilizes a combination of purified CBD and other synergistic botanical ingredients designed to naturally regulate and nourish the skin. The Pura H&W product line was developed by Avicanna and specific products have undergone clinical trials. The products are now commercial under Pura H&W or Pura Earth in Canada, Colombia Ecuador and the U.S.

The Pura H&W formulations have been developed and optimized to deliver purified, THC-free CBD in synergistic combinations with other natural ingredients known to provide specific functional benefits in skincare. CBD has been shown to promote skin health by inducing antioxidant, anti-inflammatory, and anti-apoptotic responses that could be beneficial for a variety of dermatological conditions such as eczema or atopic dermatitis. In addition, CBD can down-regulate the activity of cells that are critical in the production of skin oils and therefore may dampen the production in acne-prone skin.

About Red White & Bloom Brands Inc.

Red White & Bloom is positioning itself to be one of the top three multi-state cannabis operators active in the U.S. legal cannabis and hemp sector. Red White & Bloom is predominately focusing its investments on the major US markets, including Michigan, Illinois, California, and Florida with respect to cannabis, and the US and internationally for hemp-based CBD products.

About Avicanna

Avicanna is a Canadian commercial-stage biopharmaceutical company established in cannabinoid research, development, and evidence-based products for the global consumer, as well as medical and pharmaceutical market segments. In leading global cannabinoid advancements, Avicanna conducts most of its research in Canada at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS Discovery District. The company actively collaborates with leading Canadian academic and medical institutions. Avicanna has established an industry-leading scientific platform including advanced R&D and clinical development which has led to the commercialization of over twenty products across four main market segments:

• Medical Cannabis & Wellness Products: Marketed under the RHO Phyto brand, or Magisterial Preparations, these medical and wellness products are an advanced line of pharmaceutical-grade cannabis products containing varying ratios of CBD and tetrahydrocannabinol (“THC”). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The advanced formulary is marketed with consumer, patient and medical community education and training. Avicanna’s medical and wellness product portfolio also forms the foundation of the Company’s pharmaceutical pipeline with the contribution of the formulations that form the basis of the products as well as the data generated from sales and participation of the products in real world evidence studies.
• Pharmaceutical Pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates which are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates provide solutions for unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna’s first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America.
• Cannabis Raw Materials, Seeds, and Bulk Formulations: Marketed under the Aureus brand, the Company’s raw material business has successfully completed sales to 11 countries. Aureus offers cannabis dried flower, standardized seeds, full spectrum extracts, and cannabinoid distillates, isolated cannabinoids (CBD, THC, CBG and other rare cannabinoids), and bulk formulations derived from hemp and cannabis cultivars through its sustainable, economical, and industrial-scale subsidiaries based in Colombia. The majority of the Aureus products are produced at Santa Marta Golden Hemp S.A.S. (“SMGH”), the Company’s majority-owned subsidiary, which is also Good Agricultural and Collection Practices (“GACP”) certified and has United States Department of Agriculture (“USDA”) National Organic Program certification for its hemp cultivar.

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, contact Ivana Maric by email at [email protected] or follow us on social media on LinkedIn, Twitter, Facebook or Instagram.

The Company posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCFXPBGdKSxOUOf_VZoSFSUA.

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions and includes, without limitation, statements with respect to the Company’s anticipated growth plans, anticipated market opportunities as a result of the introduction of cannabinoid-based cosmetics, and the anticipated timing of additional products available for purchase. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, the availability of licenses, approvals and permits, and the utility and application of certain drugs and products. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated September 3, 2021 and final short form prospectus dated November 27, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com. The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

As the legal cannabis industry matures and expands, the goal of many companies is (and should be) to reach people who might not historically be cannabis consumers. According to a 2020 Gallup poll, about 12% of US adults say they smoke marijuana. This percentage has remained fairly steady over the past several years, even in the face of widespread legalization. In order to reach a much wider market, the industry clearly needs options that don’t involve smoking.

Enter cannabis-derived products, such as tinctures, creams, and edibles. People who don’t like the idea of smoking may well be inclined to try some of these alternate products. Add in the recent boom in CBD products stemming from the delisting of hemp as a dangerous drug, and suddenly you have a much more robust marketplace than the one relying on cannabis smokers. When Martha Stewart is offering CBD products, you know something has changed.

What hasn’t changed? The need to distinguish your products from the masses. One way to do that is to employ technology that makes your products more effective than others, increasing the likelihood of satisfied and repeat customers. Ovation Science Inc. (CSE:OVAT) (OTCQB:OVATF) is a company that has done the heavy lifting when it comes to topical and transdermal products with its patented Invisicare® cannabinoid delivery system. Ovation has researched, formulated, and tested over 30 products to date, all of which feature the enhanced deliverability and effectiveness of its Invisicare® technology.

Ovation Works With Licensees, Multi-State Operators

Ovation Science runs its own online sales operations, with Invibe MD targeting the health and wellness sector and ARLO CBD Beauty targeting the beauty and skincare market. Beyond those sites, however, the bulk of the company’s business model consists of partnerships with established operators in the US and Canada. Rather than trying to set up shop in various states and provinces, Ovation offers its Invisicare® technology, and the resulting products, to companies that have already navigated the various regulatory environments across the continent.

Click here to learn more about investing in patented skincare technology

The arrangements can take different forms. With its Nevada licensee, for instance, Ovation provides the Invisicare® polymer technology, the product formulations, and the accompanying intellectual property protection. The licensee takes care of product manufacturing and distribution. Other licensees may do the same, or they may choose to employ Ovation’s R&D capabilities to create entirely new products utilizing Invisicare®. Either way, Ovation has the infrastructure, the expertise, and the history to get products into the market quickly for its partners.

Ovation’s technology is scalable to fit whatever the licensee’s requirements and capabilities may be. The company makes it as easy as possible for its partners to create new lines of widely-appealing cannabis-derived products, improve existing product lines, or simply market Ovation’s existing products under their own brand.

The key for Ovation’s exclusive partners is the performance of the product, and the protection of knowing nobody else can make those products in a particular market. The performance is really impressive. The company tested its topical (ingredients to be delivered ON the skin) formulations against a number of leading CBD topicals. The results were staggering, with Invisicare® products demonstrating a 40% active ingredient release rate over a two hour period compared to an average of 3% for the other creams tested. Results were similar for transdermal (ingredients to be delivered THROUGH the skin) formulas, with Invisicare® providing an 80% penetration rate after six hours compared to 10% to 25% for the other products.

Click here to learn more about investing in patented skincare technology

Ovation Science is Worth a Look

Whether you are a cannabis retailer looking for a competitive advantage in the booming cannabis-derived products space, or an investor looking for credible and compelling cannabis companies in the public markets, Ovation Science may be worth the time to investigate. The company brings 20 years of patent-protected scientific research and development to a product space that previously has been long on claims and short on proof. It’s a young industry with loads of upside for innovators such as Ovation Science.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.

With the quickly expanding legal cannabis market finding its legs after years of prohibition, there are several hurdles remaining before the plant and its cannabis-derived product offspring are fully accepted by mainstream society. First and foremost is, of course, full legalization. From that important step everything follows, from banking regulations to changes in incarceration to consumer acceptance. But there is a factor that could serve to speed up the process – scientific research. The more cannabis is proven to be safe and controllable and effective as a medicine, the more likely it is that the powers that be will remove the last remaining barriers to a relatively free market for cannabis products.

In this regard, Ovation Science Inc. (CSE:OVAT) (OTCQB:OVATF) is a leader in the cannabis-derived products sector of the industry. The company has taken its deep pharmaceutical background and focused on developing an advanced, patented, effective, and safe cannabinoid delivery technology called Invisicare®. The system efficiently delivers active ingredients such as THC and CBD in both topical and transdermal applications. To date, Ovation has created over 30 product formulations utilizing Invisicare®. The company has its own consumer product lines Invibe®MD and Arlo CBD Beauty which it sells through its own e-commerce portals while simultaneously licensing their formulations to state operators who then manufacture and market Ovation’s formulations in their designated territory.

We recently interviewed Ovation Science CEO and Co-Founder Terry Howlett about various aspects of the company, its technology, and the market opportunities for Invisicare® products. You can see parts of the conversation here in this article:

Click here to learn more about investing in patented skincare technology

Rooted in Pharmaceutical Science

Ovation’s Head of Product Development, James Roszell, PhD, is a doctoral chemist and leads the team of researchers for the company. He has spent the better part of 20 years developing, testing, refining, and perfecting the Invisicare® technology. He is backed by a Medical Dermatology Advisory Board consisting of dermatology experts based in Canada, the United States, and the United Kingdom. Board members include the former president of the Canadian Dermatology Association, researchers whose work has been published hundreds of times, the editor of a peer-reviewed dermatology journal, and professors at esteemed universities such as Harvard, Yale, University of British Columbia, and the University of Toronto.

The goal of this Advisory Board is to reinforce the science behind its products by providing clinical, scientific, research, and strategic advice to Ovation as it continues to develop and launch Invisicare-based products. It’s a marriage of respected scientists and proven products that is just what the industry needs to achieve further validation with both regulators and consumers alike.

Skincare and Beauty Are Lucrative Markets

Cannabinoids, the active ingredients of cannabis including CBD and THC, are proliferating in topical creams and ointments throughout the world. Applications range from medicinal products meant to address arthritis and chronic pain to beauty creams meant to enhance skin elasticity and health. CBD-infused topicals are expected to reach $4.5 billion in sales by 2025, according to Cultivating Wellness, which represents a 540% increase since 2020.

Invisicare® technology addresses this explosive market by greatly enhancing the delivery of the active ingredients. One major factor issue with traditional topical products is that cannabinoids are hydrophobic – they don’t mix with water very well at all. Human bodies, meanwhile, are famously made of about 60% water. Another issue with topical applications (think sunscreen) is they tend to wear off fairly quickly, meaning that a large percentage of active ingredients don’t penetrate the skin and deliver benefits.

Ovation’s technology ensures much more complete and long lasting delivery for both topical and transdermal applications. The company tested its topical (ingredients to be delivered ON the skin) formulations against a number of leading CBD topicals. The results were staggering, with Invisicare® products demonstrating a 40% active ingredient release rate over a two hour period compared to an average of 3% for the other creams tested. Results were similar for transdermal (ingredients to be delivered THROUGH the skin; like a “patchless patch”) formulas, with Invisicare® providing an 80% penetration rate after six hours compared to 10% to 25% for other products.

What’s Next

Ovation Science is currently investigating partnerships and licensing opportunities with qualified operators in Canada and the United States. Looking to expand on its successful collaboration with its current licensee in Nevada, Ovation’s approach is to develop and produce effective Invisicare® topicals and transdermal cream formulations for licensed operators in key markets across North America and eventually the world. It’s a fairly low overhead, recurring revenue model that allows each company in the partnership to focus on what they do best. Ovation brings the science and expertise, along with its intellectual property protection, while the partner brings distribution, sales, and marketing.

In a young, formerly illegal marketplace like the cannabis industry, scientifically-backed and patented technologies like Invisicare® represent a major step toward broad acceptance. Keep an eye on Ovation Science as it spreads the word about, and the sales of, its innovative products all powered by a breakthrough delivery solution.

Click here to learn more about investing in patented skincare technology

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Even with medical marijuana being legal in Canada for years, regulations are still a bird’s nest being untangled to this day. There are practical limits and issues that consumers must deal with regularly to receive government reimbursement that often times require the assistance of a professional skilled in the process.

RYAH Medtech Inc. recognizes this fact and is getting proactive on the matter, recently joining forces with soscannabis.com, a law firm specializing in helping people that use doctor-prescribed medical cannabis to seek retroactive and prospective monetary reimbursement through claims made to governmental organizations.

RYAH and SOS Cannabis

RYAH is positioned at the intersection of medical plant intake, high tech and big data. The company has developed and is now commercializing the world’s first dose-measuring vaporizer that allows patients to precisely and automatically track and control how much cannabis (or any other plant) they inhale through the vaporizer, collecting and sharing the HIPAA-compliant data with their physician.  

Through an associated application, the patient automatically has a full data set about the exact strain, heating, dosage and effects. Armed with this information, the patient can then work with a doctor about making informed adjustments to dial-in a personalized prescription to achieve the desired benefit in a way that replaces antiquated paper documentation.

By aggregating the data and using artificial intelligence, RYAH is seeking to build the most robust library of every medical plant life cycle in the industry for predictive analysis. Beyond the patient and doctor, the data has meaningful applications for growers, dispensaries and licensed processors to monitor and manage cannabis strains and the effect it has on different patients. 

Click Here for Additional Investor Information and Corporate Updates

From its headquarters in Quebec, SOS Cannabis is more than just a seasoned multi-disciplinary law firm with expertise in medical cannabis reimbursement.  The company also provides referral services to a network of doctors and medical cannabis suppliers.  

The Partnership 

There are strong synergies between SOS Cannabis and RYAH to ensure patients are getting the cannabis that they need for their malady and being properly reimbursed. Per the new pact, Canadian patients will have the opportunity to obtain free legal representation from SOS Cannabis for pursuing reimbursement from different government agencies for purchasing RYAH’s Health Canada Class I dose-measuring vaporizer and proprietary dry-herb cartridges.

In June, RYAH entered the Canadian markets, signing a distribution agreement with licensed producer Northern Green Canada to put the eponymous vaporizers and cartridges on shelves across the country.

Through the partnership with SOS Cannabis, Canadian patients using the RYAH products will be able to look to SOS Cannabis to prepare a case file and seek reimbursement at no cost.  The relationship is expected to widen RYAH’s Canadian footprint to provide doctors and patients a complete solution and the company a unique opportunity to bridge what can be a challenging barrier to market entry.

Click Here for Additional Investor Information and Corporate Updates

“RYAH’s focus on providing patients with a world-class dose-measuring, strain analytics and real-time feedback capability is much needed in the plant-based medical arena,” said Maitre Robert Astell, President of SOS Cannabis, in a statement about the new partnership.

Mr. Astell continued, “We look forward to onboarding RYAH consumers into our fully-automated registration platform and to provide them with a state-of-the-art case management service in fulfilling their need for economic assistance in providing cannabis-based medicine products.”

RYAH Coming Public 

Based in New York City, RYAH is extending its market presence throughout Canada and the U.S., recently placing its product in retail locations in Oklahoma, Washington and Maryland. The accord with Northern Green Canada also opens the door to European markets through Northern Green’s distribution channels there. RYAH received its CE Mark for European commercialization in June, 2019.

The company is in the process of joining the public domain on the Canadian Securities Exchange with the ticker “RYAH” currently pending as the documentation is finalized for a reverse takeover of Prime Blockchain Inc. RYAH is bringing a comprehensive medtech solution that the company believes is filling a gaping void in healthcare to personalize cannabis prescriptions.

Click Here for Additional Investor Information and Corporate Updates

To Stay Up to Date with Ryah Click Here

For Additional Information on soscannabis.com click here

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

As an emerging and relatively new line of business, cannabis has already proven itself to be a powerhouse of a market. The global cannabis industry’s revenue ballooned to US $12.2 billion in 2018, with predictions that it will reach $16.9 billion in 2019, according to BDS Analytics.

The burgeoning industry is setting trends in many ways, not the least of which is the role that women are playing across the cannabis landscape. A new report by Vangst surveyed 166 cannabis companies in the US, and found that women represent 38.5% of the employees, a much higher proportion than in other industries, such as tech, construction, and beverage and tobacco.

Of these women, 17.6% held the role of ‘Director’ or ‘Executive.’ 43% of all companies who took part in the survey had a majority of female employees, with seven of these companies being comprised of all-women teams.

For a new industry, this is an exciting trend. Having diversified leadership gives strength to any team, a fact that is illustrated by the culture at The Yield Growth Corp. (CNSX: BOSS) (OTCQB:BOSQF) (Frankfurt:YG3). Headed by CEO Penny Green and a strong team of women leaders, this fresh and innovative company has already had great success in the cannabis industry and, with the continued collaboration of this team of executives, the future looks bright.

Click here to receive an investor deck and corporate updates

Leaders With Proven Expertise

With over two decades experience building companies, Penny Green is now the Director, President and CEO of The Yield Growth Corp. and CEO of Urban Juve. She has worked in many industries, ranging from music to pharmaceuticals, law to blockchain technology.

Her dossier of public successes is impressive. She was recognised on PROFIT Magazine’s W100 of top Canadian entrepreneurs. Bacchus Law Corporation was in the PROFIT 500 Fastest Growing Companies in 2015 and 2016, when it was under her leadership as CEO. Penny also has substantial experience in capital markets, and has been involved in over 100 private to public companies.

Amy Frankel is another key component of this flourishing company. She is Vice President Licensing & General Counsel to The Yield Growth Corp., and has over 15 years experience in this role building and expanding international brands.

Amy was Co-General Counsel of Aritzia LP (TSX: ATZ). During her time there, annual revenues increased around 100%, jumping from $400 million to $743 million. Amy was also Associate General Counsel of Skechers USA Inc. (NYSE: SKX), where annual revenues increased by approximately 50%. She has expertise in negotiating licensing deals, forming intellectual property strategies and managing international intellectual property portfolios.

Another leader who has a history with Aritzia is Tamara Melck, Chief Operating Officer for The Yield Growth Corp. Tamara has extensive experience in scaling operations. She was a key component in the growth of Aritzia, where she was Vice President, Corporate Operations and Executive Vice President. When she left the company in 2017, it had reached a market capitalization of over US $1 billion. Tamara was also a member and former chair of the Executive Committee of Aritzia.

Click here to receive an investor deck and corporate updates

Urban Juve’s Impressive Line Up of Leaders

The Urban Juve line is built on ancient Indian Ayurvedic wisdom fused with advanced science, and the leaders at Yield Growth knew they would have to find someone with a commendable background in this discipline. This search led them to Bhavna Solecki.

With over 30 years of Ayurvedic practice, Bhavna is at the centre of Urban Juve’s new generation of products, and oversees its product research, development and production. In 2003, she launched Samadhi Mobile Services, where she led 25 Ayurvedic practitioners on high-profile contracts including George Michael and David Beckham, before developing Inner Evolution Healing Centre Ltd. in 2011 to teach and enable Ayurvedic practitioners.

In 2017, her lifelong experience in Ayurvedic techniques led to the foundation of Urban Juve, alongside Penny Green. As Ayurveda Senior Research Scientist, she ensures compliance with Health Canada regulations, develops educational literature for staff and customers, and incorporates new technology into the supply chain.

Click here to receive an investor deck and corporate updates

With Bhavna set to oversee the development of Urban Juve products, Yield Growth needed to appoint a President of Urban Juve with a background in the health and beauty industry. Enter Sandi Lesueur, who has designed and launched several product lines for physicians and celebrities, including dermatologist Dr. Jason Rivers and Oprah Winfrey’s makeup artist, Derrick Rutledge at OOH Lifestyle. During her eight year tenure, Sandi played a huge role in the astronomical rise of M.A.C Cosmetics, where she helped the company grow from 3 stores to 88 across Canada.

Sandi also served as CEO of Riversol Skin Care Solutions Inc. where she collaborated with the Vice President of the Dermatology Association of Canada, Dr. Jason Rivers, to develop the company, and founded the second line of Riversol MD.

Her knowledge of the health and wellness industry led her to Urban Juve, where she is now President and on track to position the company as a globally successful brand.

Impressive Public and Investor Relations

Krystal Pineo is the Director of The Yield Growth Corp. She has over eight years experience as an early stage investor and fundraiser for venture capital projects. Krystal founded KP Capital Inc, a family office that invests in early stage startups, and she is also the chief financial officer and director.

Krystal has an impressive global network within the cannabis industry, which led to Urban Juve being included in this year’s pre-Oscar event.

Working alongside Krystal is Kristina Pillon, head of Investor Relations. Kristina joined the Yield Growth Corp. in November 2018. She has an extensive background in public relations and marketing, and nearly 10 years experience in capital markets, where she focussed on small cap metals and mining in a number of roles, including investor relations, marketing, and institutional equity sales. She also has six years experience at Red Cloud Klondike Strike, where she worked in investor relations and institutional equity sales.

Click here to receive an investor deck and corporate updates

Women Set on Success

Yield Growth is a prime example of the refreshing trend toward diversity throughout the cannabis world. The company is driven by women from a multitude of backgrounds and disciplines, all successful in their own right, and all positioned to take the company to the next level. Keep an eye on this group of women as The Yield Growth Corp. continues to grow its product line and retail footprint across North America and internationally. They mean business, and business is good.

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

About Joy Crosby

The last six weeks have seen major strides taken by The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF) (Frankfurt:YG3) to maintain their position as an exciting, forward-thinking and innovative cannabis company. An organisation dedicated to disrupting the wellness industry with revolutionary cannabis and hemp-based products, Yield Growth continues to make advances; it has released new products, continued to build and strengthen strategic alliances, and even begun to tackle the global market.

Wright & Well Enters Colorado’s Legal Cannabis Industry

Wright & Well, a subsidiary of Yield Growth, is a bold brand that aims to help relieve pain and anxiety through their line of THC and CBD based oils, gels, balms and other topicals.

On June 20th, the Oregon Liquor Control Commission (OLCC) gave final packaging approval for an additional three cannabis products to be distributed in Oregon. With this in place, Wright & Well will now begin manufacturing on all nine of their products.

According to Statista, legal sales of cannabis in the state of Oregon alone are projected to exceed US $1 billion by 2023, making this a major market to tackle, and an ideal blueprint for the brand as other jurisdictions across the country legalise the sale of cannabis and cannabis based products. Wright & Well jumped into the market early on, and are likely to be an important part of the Yield Growth roster as cannabis trends develop across the country.

Click here to receive an investor deck and corporate updates

Urban Juve Maintains Notable Position in the Beauty World

Urban Juve is Yield Growth’s flagship brand, which blends ancient Ayurvedic knowledge with cutting edge science and technology to produce a proprietary skincare and wellness line of products, all of which are infused with hemp root and seed oil.

The company recently announced an alliance with beauty giant ipsy, the world’s leading beauty commerce community with over three million monthly members. Part of the alliance included the sale of Urban Juve products on Shopper, ipsy’s exclusive commerce marketplace, and Yield Growth has announced that this is now live.

With the global wellness market worth US $4.2 trillion according to the Global Wellness Institute, analysts now predict that CBD infused products will be a huge part of the industry, with Hemp Industry Daily projecting that within the US, this niche will grow to US $7 billion by 2023. Between their strategic alliances and wide-reaching marketing campaign, Urban Juve has positioned itself to be at the forefront of this new market.

Continuing to Meet Consumer Demands

Urban Juve has seen such positive responses from customers that on July 5th they announced the launch of three new Hemp Daily Ritual Kits, that feature the brand’s most loved products in a curated package.

The kits were launched partly in response to consumer’s who love the products and want to share them with others. ‘Whether personal gifts or professional-volume gifting, our new offering is just what customers are looking for, and our strategic focus on the gift-giving customer helps to generate additional revenue for the brand,” says Sandi Lesueur, president of Urban Juve.

The company continues to identify ways in which to reach new customers, while also maintaining a dedication to their existing customer base.

Click here to receive an investor deck and corporate updates

Identifying Opportunities for Greater Revenue

Off the success of their existing brands, Yield Growth has invested time and money into the research and production of additional products. On June 25th, the company announced that it has completed testing on nine new products. The products contain hemp and other botanicals and have passed stability and preservation challenge tests at a laboratory in British Columbia.

The nine products include eye cream, deodorant, facial cleansers, facial oils and face masks. All the formulas in Yield Growth’s products are produced with the highest quality essential oils and pure botanical extracts. And in response to growing consumer trends, the company maintains a dedication to cruelty free practices.

With Jefferies financial research group’s estimation that the CBD Beauty Market will reach US $25 billion in ten years and amass 15% of the total skincare industry, Yield Growth is wise to continue to invest in this segment. With plans to launch several brands in California within the next 4 months, Yield Growth continues to prove itself as a force to be reckoned with in the wellness and CBD crossover market.

Going Global: Agreements Underway in Europe

In one of its most exciting reveals, Yield Growth announced on July 2nd that its Urban Juve Anti-Ageing Serum can now be sold in the European market. A Compliance Certificate was issued by Biorius, who is acting as Urban Juve’s Responsible Person in Europe.

Yield Growth had previously signed a letter of intent with Melorganics Hellas, who will act as the exclusive retail distributor and non-exclusive e-commerce distributor for the company’s flagship brand’s products in Cyprus and Greece.

As the European Union continues to create legislation that will bring cannabis closer to the mainstream market, luxury cannabis products such as Urban Juve’s line are becoming increasingly popular. With a population of well over 500 million, the EU offers an enormous market opportunity. Urban Juve hopes to obtain Compliance Certificates for all 11 of its products in the EU, and sales of its products are expected to begin in the fall of this year.

Click here to receive an investor deck and corporate updates

Positioned to be a Leader as the Industry Develops

Yield Growth is a savvy company which manages to keep its many subsidiaries developing and growing alongside the growth of the industry. It is apt at identifying profitable market opportunities and it seizes these boldly and quickly. This, coupled with the company’s many strategic alliances has positioned Yield Growth to be a leader in the crossover market of cannabis based beauty products, both in North America and globally.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.